Stefan Knop

11PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Time-series analysisTumour immunologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|Jun 03, 2026
Epcoritamab in Richter transformation: insights from a real-world case series.

|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|Mar 13, 2026
IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Johanna M Horns, Thomas Beder, Axel Künstner

|Feb 13, 2025
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab.

Lothar Marischen, Jürgen Fritsch, Jovana Ilic

|Oct 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.

Stefan Knop, Monika Szarejko, Norbert Grząśko

Pageof 2

Frequent Collaborators

2 joint publications

Norbert Hilf

2 joint publications

Farastuk Bozorgmehr

2 joint publications

Cyrus Khandanpour

2 joint publications

Meike Hutt